Drug Trial News

RSS

NEJM publishes Celgene’s Abraxane phase III study results

Published today in the New England Journal of Medicine, a phase III clinical trial of Abraxane (paclitaxel formulated as albumin-bound nanoparticles) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months) (HR 0.72, P=0.000015)].

17 Oct 2013

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

Merck, known as MSD outside the United States and Canada, is presenting pharmacokinetic data this week on investigational formulations of a once daily dose of ISENTRESS at the 14th European AIDS Conference, sponsored by the European AIDS Clinical Society.

17 Oct 2013

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

Mutations in a gene that codes for the enzyme BRAF kinase have been associated with increased risk for papillary thyroid cancer. An early-stage clinical trial of the BRAF inhibitor vemurafenib resulted in either a partial response or stable disease in patients with PTC and BRAF mutations.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

ESTEVE, a pharmaceutical company focused on developing novel therapeutics for pain today announces positive top line results from its recently completed phase II trial, which was designed to evaluate the efficacy and safety of E-58425 in acute pain.

16 Oct 2013

Researchers test ATR-101 compound in clinical trial for adrenal cancer

One of the most challenging cancers to treat is also one of the rarest, which only adds to the challenge of finding potential new therapies.

16 Oct 2013

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Today, the Population Council presented findings from a Phase 3 clinical trial that was designed to demonstrate the safety, efficacy, and acceptability of the Council's investigational one-year contraceptive vaginal ring (CVR).

16 Oct 2013

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint.

16 Oct 2013

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.

15 Oct 2013

immatics biotechnologies closes €34 million Series D financing round

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a €34 million Series D financing round.

15 Oct 2013

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology.

15 Oct 2013

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

AstraZeneca (NYSE: AZN) today announced the results of a Phase III long-term safety and tolerability study of the once-daily 25mg dose of naloxegol, in patients with non-cancer pain and opioid-induced constipation (OIC).

15 Oct 2013

New clinical trial shows increased asthma control with FeNO-guided anti-inflammatory treatment

A new randomised clinical trial shows lower incidence of asthma exacerbations and increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti-inflammatory treatment.

11 Oct 2013

Bluhm Institute enrolls first patient in SALUS trial to evaluate movable, non-metallic heart valve

Northwestern's Bluhm Cardiovascular Institute has enrolled its first participant in SALUS, a clinical trial studying the effectiveness of a prosthetic aortic heart valve that can be placed without open-heart surgery.

10 Oct 2013

Phase 3 study of idelalisibin reports positive results in CLL patients

Following a recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early.

10 Oct 2013

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced today the continuation of the development program of Lu AE58054 for the treatment of Alzheimer's disease, initiating the first out of four phase III clinical trials with the compound.

10 Oct 2013

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer Inc. announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111).

10 Oct 2013

Vital Access launches SAVE-2 post-market clinical follow-up study

Vital Access Corporation today announced the launch of the SAVE-2 post-market clinical follow-up study. The SAVE-2 study follows the U.S. SAVE study, an IDE pivotal trial that clearly demonstrated the benefits of the VWING™ Vascular Needle Guide in restoring vascular access to hemodialysis patients with uncannulatable and deep arteriovenous fistulae.

10 Oct 2013

Study proposes novel treatment for narcolepsy

Lancet Neurology, a prestigious journal in its domain, publishes in its last issue, an article entitled "Pitolisant versus placebo and modafinil in patients with narcolepsy: a double-blind randomised trial" authored by Y. Dauvilliers and others from the HARMONY I study group which proposes a novel treatment for this orphan disease. It is accompanied by a Commentary entitled "A need for new treatments in narcolepsy".

10 Oct 2013

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin two Phase II clinical studies of ALG-1001.

10 Oct 2013

Drug Trial News

NEJM publishes Celgene’s Abraxane phase III study results

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

Researchers test ATR-101 compound in clinical trial for adrenal cancer

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

immatics biotechnologies closes €34 million Series D financing round

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

New clinical trial shows increased asthma control with FeNO-guided anti-inflammatory treatment

Bluhm Institute enrolls first patient in SALUS trial to evaluate movable, non-metallic heart valve

Phase 3 study of idelalisibin reports positive results in CLL patients

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Vital Access launches SAVE-2 post-market clinical follow-up study

Study proposes novel treatment for narcolepsy

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News